Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.

ABSTRACT:

Background

Pregabalin is a calcium channel α2δ ligand that modifies visceral hypersensitivity in IBS patients. Clinical data for pregabalin in IBS are lacking.

Aim

To test the efficacy of pregabalin on gastrointestinal symptoms in IBS patients.

Methods

A double-blind, placebo-controlled trial was performed. Adults meeting IBS Rome III criteria with ≥3 pain attacks per month were randomised to pregabalin 225 mg vs placebo twice daily for 12 weeks. Questionnaires were completed weekly. The primary endpoint was average pain Bowel Symptom Scale (BSS) scores weeks 9-12. An intention-to-treat analysis of covariance evaluated treatment effects on quantitative endpoints, adjusting for age and gender. Adequate relief and change in pain score were assessed using a chi-squared t

SUBMITTER: Saito YA 

PROVIDER: S-EPMC6349499 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature